# Cabot Corp: overview

CBT · NYSE · CIK 16040 · [Materials](/sectors/materials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/cbt.md) · [Financials](/companies/cbt/financials.md) · [Filings](/companies/cbt/filings.md) · [Insiders](/companies/cbt/insiders.md)

Latest reported revenue: [$982.0m](/filings/0001193125-26-332489.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-332489).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,001 d](/filings/0001193125-25-292412.md) | [955](/filings/0001193125-26-037240.md) | [936](/filings/0001193125-26-209067.md) | [923](/filings/0001193125-26-332489.md) | [899 d](/filings/0001193125-25-292412.md) | [849](/filings/0001193125-26-037240.md) | [904](/filings/0001193125-26-209067.md) | [982](/filings/0001193125-26-332489.md) |
| Gross margin | % | [24.0% d](/filings/0001193125-25-292412.md) | [24.6%](/filings/0001193125-26-037240.md) | [25.7%](/filings/0001193125-26-209067.md) | [26.4%](/filings/0001193125-26-332489.md) | [24.5% d](/filings/0001193125-25-292412.md) | [24.9%](/filings/0001193125-26-037240.md) | [23.2%](/filings/0001193125-26-209067.md) | [18.7%](/filings/0001193125-26-332489.md) |
| Operating margin | % | [15.0% d](/filings/0001193125-25-292412.md) | [16.2%](/filings/0001193125-26-037240.md) | [17.3%](/filings/0001193125-26-209067.md) | [18.1%](/filings/0001193125-26-332489.md) | [15.2% d](/filings/0001193125-25-292412.md) | [15.2%](/filings/0001193125-26-037240.md) | [14.3%](/filings/0001193125-26-209067.md) | [10.0%](/filings/0001193125-26-332489.md) |
| Net margin | % | [13.7% d](/filings/0001193125-25-292412.md) | [9.7%](/filings/0001193125-26-037240.md) | [10.0%](/filings/0001193125-26-209067.md) | [10.9%](/filings/0001193125-26-332489.md) | [4.8% d](/filings/0001193125-25-292412.md) | [8.6%](/filings/0001193125-26-037240.md) | [7.5%](/filings/0001193125-26-209067.md) | [0.6%](/filings/0001193125-26-332489.md) |
| Diluted EPS | $ per share | not reported | [1.67](/filings/0001193125-26-037240.md) | [1.69](/filings/0001193125-26-209067.md) | [1.86](/filings/0001193125-26-332489.md) | not reported | [1.37](/filings/0001193125-26-037240.md) | [1.27](/filings/0001193125-26-209067.md) | [0.12](/filings/0001193125-26-332489.md) |
| Free cash flow | $m | [112 d](/filings/0001193125-25-292412.md) | [47.0](/filings/0001193125-26-037240.md) | [1.0 d](/filings/0001193125-26-209067.md) | [188 d](/filings/0001193125-26-332489.md) | [155 d](/filings/0001193125-25-292412.md) | [57.0](/filings/0001193125-26-037240.md) | [32.0 d](/filings/0001193125-26-209067.md) | [37.0 d](/filings/0001193125-26-332489.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,409](/filings/0000950170-23-065844.md) | [4,321](/filings/0000950170-24-129210.md) | [3,931](/filings/0001193125-25-292412.md) | [3,994](/filings/0001193125-25-292412.md) | [3,713](/filings/0001193125-25-292412.md) |
| Gross margin | % | [23.4%](/filings/0000950170-23-065844.md) | [20.5%](/filings/0000950170-24-129210.md) | [21.3%](/filings/0001193125-25-292412.md) | [24.0%](/filings/0001193125-25-292412.md) | [25.3%](/filings/0001193125-25-292412.md) |
| Operating margin | % | [13.3%](/filings/0000950170-23-065844.md) | [9.0%](/filings/0000950170-24-129210.md) | [13.4%](/filings/0001193125-25-292412.md) | [15.4%](/filings/0001193125-25-292412.md) | [16.7%](/filings/0001193125-25-292412.md) |
| Net margin | % | [7.3%](/filings/0000950170-23-065844.md) | [4.8%](/filings/0000950170-24-129210.md) | [11.3%](/filings/0001193125-25-292412.md) | [9.5%](/filings/0001193125-25-292412.md) | [8.9%](/filings/0001193125-25-292412.md) |
| Diluted EPS | $ per share | [4.34](/filings/0000950170-23-065844.md) | [3.62](/filings/0000950170-24-129210.md) | [7.73](/filings/0001193125-25-292412.md) | [6.72](/filings/0001193125-25-292412.md) | [6.02](/filings/0001193125-25-292412.md) |
| Free cash flow | $m | [62.0](/filings/0000950170-23-065844.md) | [(111)](/filings/0000950170-24-129210.md) | [351](/filings/0001193125-25-292412.md) | [451](/filings/0001193125-25-292412.md) | [391](/filings/0001193125-25-292412.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cbt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $633.3m | 6,973,153 |  | Added +357,102 |
| [EARNEST PARTNERS LLC](/funds/1102578.md) | 2026-06-30 | $303.9m | 3,345,689 |  | Added +187,072 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $279.4m | 3,076,935 |  | Reduced −44,407 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $251.4m | 2,768,176 |  | Added +530,685 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $219.5m | 2,416,471 |  | Reduced −1,149,701 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $210.8m | 2,321,142 |  | Reduced −3,165 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $196.7m | 2,165,434 |  | Added +138,098 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $182.0m | 2,003,514 |  | Reduced −44,746 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $174.9m | 1,926,205 |  | Added +183,423 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $161.6m | 1,778,678 |  | Added +423,987 |

## Recent filings

[All 1,859 filings](/companies/cbt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-15 | 12:59 ET | [8-K](/filings/0001193125-26-391407.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-391407 |
| 2026-08-21 | 20:12 ET | [8-K](/filings/0001193125-26-361109.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-361109 |
| 2026-08-14 | 20:22 ET | [8-K](/filings/0001193125-26-352348.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-352348 |
| 2026-08-04 | 18:58 ET | [10-Q](/filings/0001193125-26-332489.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332489 |
| 2026-08-03 | 20:39 ET | [8-K](/filings/0001193125-26-330708.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-330708 |
| 2026-07-30 | 12:35 ET | [8-K](/filings/0001193125-26-325036.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-325036 |
| 2026-05-14 | 12:00 ET | [8-K](/filings/0001193125-26-222854.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-222854 |
| 2026-05-06 | 20:23 ET | [10-Q](/filings/0001193125-26-209067.md) | Quarterly report, period 2026-03-31 | 0001193125-26-209067 |
| 2026-05-05 | 21:01 ET | [8-K](/filings/0001193125-26-206708.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206708 |
| 2026-03-17 | 19:57 ET | [8-K](/filings/0001193125-26-110647.md) | 5.07 Shareholder vote results | 0001193125-26-110647 |

## Latest annual report

[Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001193125-25-292412.md), filed Nov 24, 2025.

## Forecast league

Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/326cc58f-76f5-47b1-8025-10472b27049c)

## About the filer

- CIK: 16040
- Tickers: CBT
- Exchange: NYSE
- SIC code: 2890 Miscellaneous Chemical Products
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.